

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Halle MORTON et al.

Application No.: 09/889,867

Filed: Int'l.: January 20, 2000

For: COMBINATION CHAPERONIN 10 AND
BETA-INTERFERON THERAPY FOR
MULTIPLE SCLEROSIS (As Amended)

Confirmation No.: 3108

Art Unit: 1647

Examiner:
Jegatheesan Seharaseyon, Ph.D.

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RCE RESPONSE AND AMENDMENT

Dear Sir:

Responsive to the Final Office Action mailed January 9, 2007 ("the Final OA"), Applicants respectfully request entry of the amendments and consideration of the remarks set forth herein. A Notice of Appeal was submitted June 11, 2007, and a response was initially due August 11, 2007. Applicants herein submit a petition for a two month extension of time to October 11, 2007, under 37 C.F.R. §1.136, with the appropriate fee under 37 C.F.R. §1.17. Accordingly, this RCE amendment and response is timely filed.

Applicants respectfully request entry of the amendments and consideration of the remarks set forth herein. Reconsideration is respectfully requested.

This response is accompanied by a request for continued examination (RCE) under 37 C.F.R. § 1.114. Thus, the finality of the outstanding final office action will be withdrawn and Applicants are entitled to have this submission entered and considered on the merits. Reconsideration is respectfully requested.

Amendments to the claims are reflected in the listing of claims which begin on page 3 of this paper.

Remarks begin on page 8 of this paper.

The following documents are enclosed herewith:

- Transmittal letter, petition for a one month extension of time;
- Request for continued examination (RCE) under 37 C.F.R. §1.114;
- Appendix:
- Barbero (2004) J. Neurol. Sci. Jul; 222(1-2):13-19;
- Arnason (2005) J. Neurol. 252 [Suppl 3]:III/28-III/33);
- Durelli (2005) J. Neurol. 252 [Suppl 3]: III/38-III/43.